Statement: The only type of adverse event recorded by both the secondary trial and the primary trial is Diarrhoea and Abdominal pain.
Primary_evidence: Adverse Events 1:   Total: 10/76 (13.16%)   Sickle cell anaemia with crisis 1/76 (1.32%)   Diarrhoea 1/76 (1.32%)   Pyrexia 1/76 (1.32%)   Chest pain 1/76 (1.32%)   Complication associated with device 1/76 (1.32%)   General physical health deterioration 0/76 (0.00%)   Device related infection 2/76 (2.63%)   Pneumonia 1/76 (1.32%)   Atypical pneumonia 1/76 (1.32%)   Dehydration 1/76 (1.32%) Adverse Events 2:   Total: 3/75 (4.00%)   Sickle cell anaemia with crisis 0/75 (0.00%)   Diarrhoea 0/75 (0.00%)   Pyrexia 1/75 (1.33%)   Chest pain 0/75 (0.00%)   Complication associated with device 0/75 (0.00%)   General physical health deterioration 1/75 (1.33%)   Device related infection 0/75 (0.00%)   Pneumonia 1/75 (1.33%)   Atypical pneumonia 0/75 (0.00%)   Dehydration 0/75 (0.00%)
Secondary_evidence: Adverse Events 1:   Total: 16/56 (28.57%)   Pancytopenia 0/56 (0.00%)   Pericarditis 0/56 (0.00%)   Abdominal pain 1/56 (1.79%)   Anal fissure 1/56 (1.79%)   Ascites 1/56 (1.79%)   Constipation 0/56 (0.00%)   Diarrhoea 1/56 (1.79%)   Nausea 0/56 (0.00%)   Oesophageal pain 0/56 (0.00%)   Vomiting 0/56 (0.00%)   Disease progression 2/56 (3.57%)   Infusion related reaction 1/56 (1.79%)   Pain 0/56 (0.00%) Adverse Events 2:   Total: 11/37 (29.73%)   Pancytopenia 1/37 (2.70%)   Pericarditis 1/37 (2.70%)   Abdominal pain 2/37 (5.41%)   Anal fissure 0/37 (0.00%)   Ascites 0/37 (0.00%)   Constipation 1/37 (2.70%)   Diarrhoea 1/37 (2.70%)   Nausea 2/37 (5.41%)   Oesophageal pain 1/37 (2.70%)   Vomiting 2/37 (5.41%)   Disease progression 2/37 (5.41%)   Infusion related reaction 0/37 (0.00%)   Pain 1/37 (2.70%)